

Gagnon et al. 3

53 **Introduction**

54

55 Angiopoietin-like 4 (ANGPTL4) plays a key role in lipoprotein-lipid metabolism and energy 56 patitioning. ANGPTL4 inhibits lipoprotein lipase (LPL) mediated lipoprotein uptake by adipose 57 tissue leading to a decrease in circulating lipoproteins and lipids (Kersten 2021). Carriers of the 58 E40K loss-of-function variant in *ANGPTL4* are characterized by lower plasma triglyceride levels 59 as well as lower rates of coronary heart disease (CAD) and type 2 diabetes (T2D) (Dewey et al. 60 2016; Gusarova et al. 2018). These genetic data suggest that ANGPTL4 inhibition may become a 61 pharmacological strategy of interest in the prevention or treatment of cardiometabolic diseases, 62 especially in individuals with elevated triglycerides levels. For ANGPTL4 to be a viable target, 63 its inhibition must be proven safe. Concerns about the safety of ANGPTL4 inhibition arise from 64 the observation that monoclonal antibody-induced ANGPTL4 inhibition in mice and monkeys 65 led to the accumulation of lipid in mesenteric lymph nodes (Dewey et al. 2016). Consequently, 66 the safety of ANGPTL4 inhibition in humans remains uncertain. 67 68 A powerful method to understand the functional impact of proteins such as ANGPTL4 is to 69 leverage their loss-of-function variants. Genetic variations are randomly distributed during 70 gametogenesis and remain constant throughout life, making their associations with diseases 71 unlikely to be influenced by environmental confounding factors or reverse causality, hence likely 72 to be causal. The most common functional variant in ANGPTL4 is E40K, which substitutes a 73 glutamic acid for a lysine giving rise to an unstable ANGPTL4 protein (Yin et al. 2009). The 74 frequency of E40K carriers varies from 0.1% in individuals of African ancestry, to 75 approximately 3% in individuals of European ancestry to 18% in a Tunisian population (Abid et 76 al. 2016). The well-replicated associations of E40K with lipid levels and diseases could be 77 spurious (i.e., non-causal) if driven by another correlated variant. In fact, the previous cohort 78 studies on E40K carriers were unable to distinguish true causal effects from confounding due to 79 linkage disequilibrium (Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia 80 Investigators et al. 2016; Dewey et al. 2016; Gusarova et al. 2018). To address linkage

81 disequilibrium confounding, it is essential to employ fine mapping methods such as CoPheScan

82 (Coloc adapted Phenome-wide Scan) (Manipur et al. 2023). CoPheScan is a Bayesian approach

Gagnon et al. 5

114 the substantial fraction of hospital-based recruitment, FinnGen is enriched for disease end-points.

115 All end-points were adjusted for sex, age, genotyping batch and ten first principal genetic

116 components as covariates prior to GWAS. All GWAS were performed using the SAIGE

- 117 (v.0.35.8.8) algorithm (Zhou et al. 2018).
- 118

119 *Genetic colocalisation*

120 To test for confounding due to linkage disequilibrium, we used the CoPheScan algorithm. 121 CoPheScan is a Bayesian approach that integrates the linkage disequilibrium matrix and 122 information on the neighbouring variants to address linkage disequilibrium confounding.. We 123 used CoPheScan to help distinguish the E40K associations with traits that might be confounded 124 by linkage disequilibrium from those that are true effects. We included all SNPs within 300 Kb 125 upstream or downstream of the *ANGPTL4* gene region and systematically tested whether the 126 E40K was the likely causal variant for all tested traits. CoPheScan priors were computed using a 127 hierarchical Bayesian model. Bayes factors were calculated using the SuSIE algorithm allowing 128 for multiple causal variants. SuSIE was computed with a LD matrix obtained using the 1000- 129 genome reference panel of individuals of European ancestry (Zou et al. 2022). CoPheScan 130 returns posterior probability for three mutually exclusive hypotheses: $H_n=N_0$ association with the 131 query trait; $H_a =$ Causal association of a variant other than the query variant with the query trait; 132 and H_c=Causal association of the query variant with the query trait. A high H_c supports that the 133 association is not due to linkage disequilibrium.

134

135 We investigated shared genetic etiology across lipids and cardiometabolic diseases using multi-136 trait colocalization analyses with the HyPrColoc R package (Foley et al., 2021). HyPrColoc 137 extends traditional genetic colocalization methods by estimating posterior probability of more 138 than two traits sharing the same causal variants. If the traits do not share a causal SNP, a branch-139 and-bound selection algorithm is employed to highlight a subset of traits that share a causal SNP. 140 We used the default uniform prior for the analysis. Prior.1 -the prior probability of a SNP being 141 associated with one trait- was set to 1e-4 and prior.c -the probability of a SNP being associated 142 with an additional trait given that the SNP is associated with at least one other trait- was set to 143 0.02. HyPrColocalization analyses are sensitive to the choice of priors. The priors were therefore 144 iteratively incremented to assess the stability of clusters as a sensitivity analysis. All analyses

Gagnon et al. 6

145 were performed with the genetic region spanning 300 Kb around the *ANGPTL4* gene region. The 146 colocalization events were visualized with regional stack plot created with the *gassocplot* 147 package.

-
- 148

149 *ANGPTL4 loss-of-function mutations in UK Biobank*

150 Access to the UK Biobank was granted under UK Biobank application 25205. The UK Biobank 151 is a population-based cohort of approximately 500,000 participants, aged 40 to 69 years recruited 152 during 2006–2010 from several centres across the UK. We studied a subsample of 488,278 153 individuals from mixed ancestries with whole exome sequence available. These sequences were 154 annotated with the Ensembl Variant Effect Predictor (McLaren et al., 2016) to identify loss-of-155 function variants in the *ANGPTL4* gene region. Loss-of-function variants were defined as either 156 frameshift, missense, splice, nonsense, start-lost or stop-lost variants and grouped according to 157 the Phred-scaled Combined Annotation Dependent Depletion (CADD) score (Rentzsch et al., 158 2021). Noncarriers of these variants were assigned to the control group, carriers with at least one 159 variants with CADD score > 20 and significantly associated with triglycerides ($p < 0.05$) were 160 assigned to the carrier group, individuals with loss-of-function mutation CADD < 20 or not 161 associated with triglycerides were excluded. The E40K variant CADD score was 31 and it was 162 associated with triglyceride levels at p<7e-136. To specifically assess the impact of other loss-of-163 function mutations in *ANGPTL4*, the analyses were performed by including and excluding E40K

165

164 carriers.

166 We defined CAD, T2D and aortic stenosis using Hospital Episode Statistics ICD10 and OPCS4

167 codes. CAD cases were defined as participants with ICD-10 codes for MI (I21.X, I22.X, I23.X,

- 168 I24.1, or I25.2), other acute ischemic heart diseases (I24.0, I24.8-9) or chronic ischemic heart
- 169 disease (I25.0-25.1, I25.5-25.9), OPSC-4 codes for coronary artery bypass grafting (K40.1- 40.4,

170 K41.1-41.4, K45.1-45.5), for coronary angioplasty, with or without stenting (K49.1- 49.2,

171 K49.8-49.9, K50.2, K75.1-75.4, K75.8-75.9). AS cases were defined as participants with aortic

- 172 valve stenosis (I35.X). Participants with rheumatic fever (I01-9) prior to AS diagnosis were
- 173 excluded from the analysis on AS. T2D cases were defined as participants with type 2 diabetes

174 mellitus (E11, E12, E13, E14).

Gagnon et al. 7

176 To assess the association of loss-of-function mutation on the incidence of diseases, we performed 177 Cox regression. All models were adjusted for variables at recruitment including age at 178 recruitment, sex, and the first 10 principal components of ancestry. To model the lifelong effects 179 of carrier status, the follow-up was started at birth and ended at censoring, death or the date of 180 the data release (2021-11-12). Results are presented as estimated hazard ratios (HR) for incident 181 diagnosis, with 95% confidence intervals. 182 183 *Effect of LPL and hepatic lipase (HL) on cardiometabolic traits and diseases* 184 To gain insights into the mechanism linking genetic ANGPTL4 inhibition to diseases, we 185 investigated the effects of LPL and HL, two enzymes inhibited by ANGPTL4, on 186 cardiometabolic traits and diseases. LPL enhancement was proxied using all independent 187 variants $(r^2<0.1)$ 300 Kb downstream and upstream of the *LPL* gene region significantly (pval 188 <5e-8) associated with triglyceride levels (Graham et al. 2021). Similarly, HL enhancement was 189 proxied using all independent variants $(r^2<0.1)$ 300 Kb downstream and upstream of the *LIPC* 190 gene region significantly (pval<5e-8) associated with triglyceride levels. Harmonization was 191 performed by aligning the effect sizes of different studies on the same effect allele. When a 192 particular SNP was not present in the outcome datasets, we used a proxy SNPs $(r^2 > 0.8)$ obtained 193 using linkage disequilibrium information from the 1000 Genomes Project European samples. 194 Instrument strength was assessed using the F-statistic (Burgess, Thompson, and CRP CHD 195 Genetics Collaboration 2011), and the variance explained assessed using the r^2 (Pierce, Ahsan, 196 and VanderWeele 2011). The effect of each gene on cardiometabolic traits and diseases was 197 calculated using the inverse variance weighted method with multiplicative random effects 198 (Burgess, Foley, and Zuber 2018) when the number of genetic instruments were over one, or the 199 Wald ratio in the case of the E40K because the number of instruments was equal to one. We 200 compared the effect of LPL and HL on cardiometabolic traits and diseases to the ANGPTL4 201 inhibition on these same cardiometabolic traits and diseasesu using a Pearson's correlation 202 coefficient. 203 204 205 **Results** 206

Gagnon et al. 8

207 The E40K variant was associated with a more favorable lipoprotein-lipid profile, including lower 208 triglyceride and apolipoprotrein (apo) B levels, higher HDL cholesterol levels, but was not 209 associated with LDL cholesterol levels (Figure 1). Additionally, it was associated with lower 210 waist-to-hip ratio, but not with BMI, indicating a more favourable body fat distribution in 211 carriers. Information on the GWAS summary statistics used are presented in Supplementary 212 Table 1. Overall, the E40K showed favorable or neutral associations with the 20 213 cardiometabolic traits tested (Supplementary Table 2). 214 215 The E40K variant was protective for several cardiometabolic diseases including aortic stenosis 216 (odds ratio [OR] = 0.82, 95% CI=0.74 to 0.92, p=7.1e-04), CAD (OR = 0.84, 95% CI=0.81 to 217 0.87, p=3.6e-21) and T2D (OR = 0.91, 95% CI=0.87 to 0.95, p=2.8e-05) (Figure 2). The E40K 218 was also associated with lower risk of stroke, ischemic stroke and heart failure. There was no 219 evidence for an association with acute pancreatitis, chronic kidney disease, or non-alcoholic fatty 220 liver disease. The E40K was also associated with longer parental lifespan, indicating a 221 potentially favourable benefit/risk balance (Figure 1). In summary, the E40K variant was either

222 protective or neutral of all cardiometabolic diseases tested.

223

224 Other less frequent loss-of-function mutations in *ANGPTL4* were also associated with healthier 225 lipid levels and decreased risk of diseases (Figure 3). By scanning whole-exome sequence of UK 226 biobank participants, we identified 2835 carriers (excluding E40K) or 20,015 carriers (including 227 E40K) of deleterious *ANGPTL4* variants (CADD score > 20 and associated with triglycerides 228 with a p-value < 0.05). *ANGPTL4* loss-of-function carriers had lower levels of triglycerides, 229 higher levels of HDL cholesterol and lower incidence of T2D (Figure 3). When including E40K 230 carriers, loss-of-function in ANGPTL4 was associated with lower CAD incidence (Figure 3 231 panel B). When excluding E40K carriers, loss-of-function in *ANGPTL4* was associated with 232 lower CAD incidence but the association did not reach statistical significance (HR = 0.9095%) 233 CI=0.80 to 1.02, p=9.9e-02). Loss-of-function in *ANGPTL4* was associated with lower aortic 234 stenosis incidence only when including E40K carriers. The directionally consistent associations 235 of E40K and other rarer loss-of-function variant in *ANGPTL4* support the role of ANGPTL4 in 236 CAD and T2D.

Gagnon et al. 9

238 The E40K protective effects on diseases were not due to confounding by linkage disequilibrium 239 as demonstrated by colocalization algorithms. Within the *ANGPTL4* gene region +/- 300 Kb, 240 CoPheScan and HyPrColoc prioritised E40K as the unique causal variant. For example, although 241 the CoPhesScan posterior probability of E40K being the unique causal variant was 0.06% for 242 AS, this probability was 98% for T2D and 99.99 % for triglyceride levels, HDL cholesterol 243 levels, and CAD (Supplementary Table 3). These high probabilities support that E40K 244 associations are causal and unaffected by linkage disequilibrium confounding. Similarly, the 245 HyPrColoc algorithm showed a posterior probability of multi-trait colocalization of 0.79 for 246 HDL cholesterol levels, triglyceride levels, T2D, CAD and AS (Figure 4). Notably, the 247 rs116843064-A (i.e., the E40K) explained 100% of the posterior probability of multi-trait 248 colocalization, providing evidence for E40K as a shared causal variant. In summary, both 249 colocalization approaches consistently validated E40K as a reliable genetic proxy for lifelong

- 250 ANGPTL4 inhibition.
- 251

252 *Phenome-wide study of ANGPTL4 E40K in FinnGen*

253 To assess the safety of ANGPTL4 inhibition, we examined the impact of E40K on 1589 diseases 254 in FinnGen. E40K was associated with a lower risk of aortic stenosis, CAD and T2D, replicating 255 our initial results obtained through GWAS meta-analysis (Figure 5). The E40K variant was not 256 associated with lymphadenopathy, ascites, or peritonitis, as observed in whole-body *ANGPTL4* 257 knockout mice. Notably, the E40K did not significantly increase the risk of any of the other 258 diseases tested suggesting that the benefits of genetic inhibition of *ANGPTL4* may have more 259 health advantages than consequences (Supplementary Table 2).

260

261 *Exploring E40K mechanisms*

262 The impact of ANGPTL4 on diseases is likely tied to its inhibition of enzymes such as LPL

263 andHL. To shed light on this mechanism, we assessed the effect of LPL and HL on

264 cardiometabolic traits and diseases and compared their effects with those resulting from

265 ANGPTL4 inhibition (Supplementary Table 4). LPL and HL enhancement were proxied with

266 independent SNPs in their respective gene region $+/-300$ Kb significantly associated (pval<5e-8)

267 with triglycerides. Specifically LPL enhancement was proxied with 71 independent SNPs in the

268 LPL region $+/- 300$ Kb significantly associated with triglycerides ($r^2 = 1.92\%$; F-statistics = 343)

Gagnon et al. 11

300 human ANGPTL4 inhibition is further supported by a recent randomized, double-blind, placebo-301 controlled Phase I study evaluating the safety of a GalNAc conjugated ASO against ANGPTL4. 302 The treatment did not cause serious adverse events but caused mild resolving injection site

- 303 reactions (89% of treated, 0% of placebo) (K. Nilsson 2023).
- 304

305 Our results show that genetically predicted inhibition of ANGPTL4 and genetically predicted 306 enhancement of LPL have very similar effects on cardiometabolic diseases (*r*=0.85), suggesting 307 that the effects of ANGPTL4 on cardiometabolic diseases are potentially mainly mediated 308 through LPL. In support of this notion, ANGPTL4 was shown to bind and inhibit LPL (Gutgsell 309 et al. 2019). Furthermore, the E40K proxying inhibition of ANGPTL4 and rs115849089_A 310 proxying enhancement of the activity of LPL were shown to have very similar effects on 311 metabolites (r2>0.96), strongly suggesting that ANGPTL4 impacts plasma lipids exclusively via 312 LPL (Wang, n.d.; Landfors, Chorell, and Kersten 2023). ANGPTL4 could also antagonise HL, as 313 mice with hepatocyte-specific knock of ANGPTL4 have higher HL activity (Singh et al. 2021). 314 Despite the potential inhibitory effect of ANGPTl4 on HL, we did not find evidence that 315 ANGPTL4 influenced cardiometabolic disease through HL. In summary, our results and those of

316 others (Landfors, Chorell, and Kersten 2023) support that ANGPTL4 effects on diseases are

317 related to the activity of *LPL* and not *LIPC*, the gene encoding HL.

318

319 Our genetic data shows that loss-of-function variants in ANGPTL4 have no effect on 320 lipoprotein(a), no effect on LDL cholesterol, a weak effect on ApoB and a stronger effect on 321 CAD. These genetic data suggest that ANGPTL4 inhibition protects from CAD in part from 322 ApoB lowering, but also through other mechanisms. The major effect of ANGPTL4 inhibition is 323 triglyceride lowering, which has been initially argued as an independent causal factor for CAD 324 (Gotto 1998). However, this notion has recently been challenged by high throughput 325 multivariable Mendelian randomization studies showing no effect of triglyceride when ApoB is 326 taken into account (Zuber et al. 2021). Genetic data support that the clinical benefit of lowering 327 TG and LDL-C levels is proportional to the absolute change in ApoB (Ference et al. 2019), 328 further emphasizing ApoB as the main risk factor. Hence, genetic inhibition of ANGPTL4 seems 329 to reduce CAD risk not only through its lowering of ApoB-containing particle, but also possibly 330 though other mechanism. For example, our data and those of others (Aryal et al. 2018) show that

Gagnon et al. 13

- 361 All data used in this study are in the public domain. All participants provided informed consent
- 362 and study protocols were approved by their respective local ethical committees. This project was
- 363 approved by the Institutional Review Board of the Quebec Heart and Lung Institute.
- 364 *Data Availability*
- 365 All data used in this study are in the public domain. Supplementary Table 1 describes the data
- 366 used and relevant information to retrieve the summary statistics.
- 367 *Code Availability*
- 368 Code to reproduce the results of this manuscript is available on
- 369 https://github.com/gagelo01/ANGPTL4
- 370 *Competing interests*
- 371 BJA is a consultant for Novartis, Eli Lilly, Editas Medicine and Silence Therapeutics and has
- 372 received research contracts from Pfizer, Eli Lilly and Silence Therapeutics.
- 373 *Funding*
- 374 EG holds a doctoral research award from the *Fonds de recherche du Québec: Santé*. (FRQS). JB
- 375 holds a masters research award from the FRQS. ÉG holds a Doctoral Research Award from the Canadian Institutes of Health Research. BJA holds a senior scholar awards from the FRQS.
- Canadian Institutes of Health Research. BJA holds a senior scholar awards from the FRQS.
- 377 *Authors' contributions*
- 378 Data acquisition and analysis EG, JB, ÉG and ST. Conception and design EG, BJA. Drafting of
- 379 the work EG, BJA. All authors approved the final version of the manuscript.
- 380
- 381
- 382
-
- 384

383 **References**

- 385 Abid, Kaouthar, Thouraya Trimeche, Donia Mili, Mohamed Amine Msolli, Imen Trabelsi, Semir 386 Nouira, and Abderraouf Kenani. 2016. 'ANGPTL4 Variants E40K and T266M Are 387 Associated with Lower Fasting Triglyceride Levels and Predicts Cardiovascular Disease 388 Risk in Type 2 Diabetic Tunisian Population'. *Lipids in Health and Disease* 15 (March): 389 63. https://doi.org/10.1186/s12944-016-0231-6. 390 Aragam, Krishna G., Tao Jiang, Anuj Goel, Stavroula Kanoni, Brooke N. Wolford, Deepak S.
- 391 Atri, Elle M. Weeks, et al. 2022. 'Discovery and Systematic Characterization of Risk 392 Variants and Genes for Coronary Artery Disease in over a Million Participants'. *Nature*
- 393 *Genetics* 54 (12): 1803–15. https://doi.org/10.1038/s41588-022-01233-6.

Gagnon et al. 17

- 531 Mendelian Randomization Analysis Prioritizes Apolipoprotein B as Key Lipid Risk
- 532 Factor for Coronary Artery Disease'. *International Journal of Epidemiology* 50 (3): 893–
- 533 901. https://doi.org/10.1093/ije/dyaa216.
- 534

Gagnon et al. 18

Figure Legends

Figure 1. Impact of the *ANGPTL4* **loss-of function variant E40K on cardiometabolic traits.** All cardiometabolic traits have a SD of one. $ALT =$ alanine aminotransferase, $AST =$ aspartate aminotransferase, $BMI = body$ mass index, $HDL = high-density$ lipoprotein, $LDL = low-density$ lipoprotein, WHRadjBMI = waist-to-hip ratio adjusted for body mass index. $CI =$ confidence interval

Figure 2. Impact of the *ANGPTL4* **loss-of function variant E40K on cardiometabolic** diseases. NAFLD = non-alcoholic fatty liver disease. $CI =$ confidence interval and $OR =$ Odds ratio.

Figure 3. Health impact of *ANGPTL4* **loss-of function mutations in the UK Biobank.** Impact of *ANGPTL4* variants (including E40K and excluding E40K) on A) incidence of coronary artery disease, type 2 diabetes and aortic stenosis and B) high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride levels.

Figure 4. Multi-trait genetic colocalization for lipids and cardiometabolic diseases. The left panel shows the regional association plot with the highlighted genetic variant prioritized by HyPrColoc. The right panel shows the heatmap of the proportion of colocalization on different range of prior values.

Figure 5. Phenome-wide association study of the *ANGPTL4* **loss-of function variant E40K on 1589 diseases in FinnGen.** The green line is the threshold for multiple testing significance. Triangles pointing down represent negative associations (i.e., E40K lowers the risk of the disease), whereas triangles pointing up represent positive associations (i.e., E40K increases the risk of the disease). Associations that pass multiple testing correction are annotated and encompass atherosclerotic conditions and type 2 diabetes. Among the triangles pointing up, all are below the green significance line, meaning that E40K is not significantly associated with an increase risk of diseases.

Gagnon et al. 19

Figure 6. Impact on genetic inhibition of *ANGPTL4* **on cardiometabolic traits and diseases in relation with the effect on genetic enhancement of lipoprotein lipase and hepatic lipase on the same traits and diseases.** ANGPTL4 inhibition was proxied with the E40K. Lipoprotein lipase (LPL) and hepatic lipase (HL) enhancing were proxied with variants from their respective gene region significantly associated with triglyceride levels. Each effect is scaled to a one standard deviation effect on triglyceride levels. Panel A) ANGPTL4 inhibition vs. LPL enhancement. Panel B) ANGPTL4 inhibition vs. HL enhancement.

 $\ddot{}$

Outcomes	ANGPTL4 E40K	OR (95% CI)	pval
Glucose homeostasis			
Type 2 diabetes	⊢∎⊣	0.91 (0.87 to 0.95)	2.8e-05
Kidney			
Chronic Kidney disease		1.00 (0.93 to 1.07) 9.5e-01	
Lifespan			
Longevity		1 1.15 (0.98 to 1.36) 8.5e-02	
Liver			
NAFLD		1.01 (0.94 to 1.09) 8.0e-01	
Pancreas			
Acute pancreatitis		0.98 (0.90 to 1.07) 6.9e-01	
Vascular			
Aortic stenosis		0.82 (0.74 to 0.92)	7.1e-04
Coronary artery disease	⊢∎⊣	0.84 (0.81 to 0.87)	3.6e-21
Heart failure		0.93 (0.88 to 0.99) 1.7e-02	
Ischemic stroke		0.92 (0.87 to 0.98)	1.4e-02
Stroke	0.8 1.1 1.21.3 0.9 Odds ratio (95% CI)	0.94 (0.89 to 1.00)	4.4e-02

Figure 2.

\mathbf{A}

B)

Figure 4.

 $\check{ }$

Figure 6.